Prostate Cancer Screening, Diagnosis and Risk Stratification Flashcards
What is the most commonly diagnosed cancer and the second leading cause of cancer death in men in the US?
A. Lung Cancer
B. Prostate Cancer
C. Breast Cancer
D. Colorectal Cancer
B. Prostate Cancer
Explanation: The material states that prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in men in the US.
What is the approximate number of men diagnosed with prostate cancer in 2022?
A. 200,000 men
B. 250,000 men
C. 268,490 men
D. 300,000 men
C. 268,490 men
Explanation: According to the text, approximately 268,490 men were diagnosed with prostate cancer in 2022.
What is the mean age at diagnosis of prostate cancer?
A. 60 years
B. 66 years
C. 70 years
D. 75 years
B. 66 years
Explanation: The material states that the mean age at diagnosis of prostate cancer is 66 years.
What grade recommendation did the U.S. Preventive Services Task Force Recommendation change to in 2018 regarding prostate cancer screening?
A. Grade A
B. Grade B
C. Grade C
D. Grade D
C. Grade C
Explanation: The U.S. Preventive Services Task Force changed their recommendation to Grade C in 2018, indicating moderate uncertainty regarding the benefits and harms of PSA-based screening.
Which of the following organizations endorse shared decision-making for prostate cancer screening?
A. AUA
B. National Cancer Comprehensive Network
C. American Cancer Society
D. All of the above
D. All of the above
Explanation: The AUA, National Cancer Comprehensive Network, and the American Cancer Society all endorse shared decision-making for prostate cancer screening according to the provided material.
In 2022, what percentage of men are estimated to have prostate cancer-related mortality?
A. 1.5%
B. 2.4%
C. 3.2%
D. 4.0%
B. 2.4%
Explanation: The material states that 2.4% of men will have prostate cancer-related mortality in 2022.
Over what percentage of new prostate cancer cases are diagnosed in men aged 65 years and older?
A. 40%
B. 50%
C. 60%
D. 70%
C. 60%
Explanation: Over 60% of new cases are diagnosed in men aged 65 years and older, according to the material.
What change has been observed in prostate cancer in relation to the Grade D recommendation from the U.S. Preventive Services Task Force Recommendation in 2012?
A. An increase in early detection
B. An inverse stage migration
C. An increase in mortality rates
D. A decrease in diagnosis rates
B. An inverse stage migration
Explanation: The material suggests that there has been an inverse stage migration in prostate cancer associated with the Grade D recommendation.
What is the term used to describe the trend of diagnosing more advanced stages of prostate cancer, particularly after the Grade D recommendation from the U.S. Preventive Services Task Force in 2012?
A. Direct stage migration
B. Progressive stage migration
C. Inverse stage migration
D. Regressive stage migration
C. Inverse stage migration
Explanation: In the context of prostate cancer and the Grade D recommendation from the U.S. Preventive Services Task Force in 2012, the term “inverse stage migration” is used to describe a shift towards diagnosing higher-stage, more advanced prostate cancers. This is likely due to the discouragement of routine prostate-specific antigen (PSA) testing, which might have led to fewer diagnoses of early-stage, lower-risk cancers. Instead, cancers were more likely to be diagnosed when they had progressed to a later stage and were causing symptoms.
What is the mainstay of prostate cancer screening?
A. Prostate physical examination
B. Prostate-specific antigen (PSA)
C. MRI
D. CT scan
B. Prostate-specific antigen (PSA)
Explanation: The text states that PSA represents the mainstay of prostate cancer screening.
What is one reason that PSA is an imperfect screening tool?
A. PSA is not associated with prostate cancer
B. PSA can be elevated in benign conditions of the prostate
C. PSA levels are always high in men with prostate cancer
D. PSA levels cannot be measured accurately
B. PSA can be elevated in benign conditions of the prostate
Explanation: The text mentions that PSA is an imperfect screening tool because it can be elevated in benign conditions of the prostate.
According to the U.S. Preventive Services Task Force recommendations in 2018, at what age should men start considering individualized shared decision-making for prostate cancer screening?
A. 40 years old
B. 50 years old
C. 55 years old
D. 70 years old
C. 55 years old
Explanation: The 2018 recommendation from the U.S. Preventive Services Task Force endorses individualized shared decision-making for prostate cancer screening for men aged 55 to 69 years old.
According to the AUA’s best practice statement for PSA screening, what is the recommended routine screening interval to reduce the harms of screening?
A. Annually
B. Every two years or more
C. Every five years
D. Every ten years
B. Every two years or more
Explanation: The AUA recommends a routine screening interval of two years or more to reduce the harms of screening, for those men who have decided on screening through shared decision-making.
According to multiple studies, an initial PSA less than what value at ages 40-49 or 50-59 years old is associated with a low risk of incident prostate cancer?
A. 0.5 ng/ml
B. 1 ng/ml
C. 1.5 ng/ml
D. 2 ng/ml
B. 1 ng/ml
Explanation: The text indicates that an initial PSA less than 1 ng/ml at ages 40-49 or 50-59 years old is associated with a low risk of incident prostate cancer.
What phenomenon contributes to the elevation of PSA levels in the context of prostate cancer?
A. Overproduction of PSA by cancer cells
B. Disruption of glandular architecture and loss of the basal cell layer
C. Inhibition of PSA by cancer cells
D. Production of PSA by other organs
B. Disruption of glandular architecture and loss of the basal cell layer
Explanation: The text states that the pathophysiology of PSA elevation in prostate cancer involves the disruption of the glandular architecture and loss of the basal cell layer, which leads to PSA leaching into the bloodstream.
Which study found a statistically significant relative reduction of 21% in prostate cancer mortality at 11 years with prostate cancer screening?
A. The U.S. Preventive Services Task Force Recommendation
B. The Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial
C. The European Randomized Study of Screening for Prostate Cancer (ERSPC)
D. The AUA Best Practice Statement for PSA Screening
C. The European Randomized Study of Screening for Prostate Cancer (ERSPC)
Explanation: The ERSPC reported a statistically significant relative reduction of 21% in prostate cancer mortality at 11 years with prostate cancer screening.
According to the National Comprehensive Cancer Network (NCCN) Prostate Cancer Early Detection guidelines, at what age is it currently recommended to start screening?
A. 40 years old
B. 45 years old
C. 55 years old
D. 65 years old
B. 45 years old
Explanation: The NCCN guidelines currently recommend starting screening at age 45 years old.
According to the AUA, which group of men should consider PSA screening through shared decision-making?
A. Men under age 40 years
B. Men between ages 40 to 54 years at average risk
C. Men ages 55 to 69 years
D. Men over age 70
C. Men ages 55 to 69 years
Explanation: The AUA recommends shared decision-making for men aged 55 to 69 years considering PSA screening.
In high-risk populations, at what age should prostate cancer screening start?
A. 30 years old
B. 40 years old
C. 50 years old
D. 60 years old
B. 40 years old
Explanation: The text mentions that screening should start at age 40 in high-risk populations, such as patients with a family history of certain cancers, Black/African American men, and patients with certain germline mutations.
What does Multiparametric Magnetic Resonance Imaging (mpMRI) include in its acquisition?
A. T1- and T2-weighted images, diffusion-weighted images (DWI), and dynamic contrast enhanced images (DCE)
B. T1- and T2-weighted images, and diffusion-weighted images (DWI) only
C. T1- and T2-weighted images only
D. T1- and T2-weighted images, and dynamic contrast enhanced images (DCE) only
A. T1- and T2-weighted images, diffusion-weighted images (DWI), and dynamic contrast enhanced images (DCE)
Explanation: The text mentions that mpMRI involves – at the minimum - the acquisition of T1- and T2-weighted images, diffusion-weighted images (DWI), and dynamic contrast enhanced images (DCE).
According to the PROMIS study, how much more sensitive is mpMRI compared to TRUS biopsy for clinically significant cancer?
A. 41%
B. 52%
C. 93%
D. 100%
C. 93%
Explanation: The PROMIS study found that for clinically significant cancer, mpMRI was more sensitive (93%).
In the PRECISION study, in which group was clinically significant prostate cancer detected more?
A. The mpMRI targeted biopsy group
B. The TRUS biopsy group
C. Both groups had the same detection rate
D. The study did not specify
A. The mpMRI targeted biopsy group
Explanation: The PRECISION study found that clinically significant prostate cancer was detected in 38% of the mpMRI targeted biopsy group as compared to 26% of the TRUS biopsy group.
According to the AUA position, what is recommended for men undergoing MRI-targeted sampling for prostate cancer?
A. Only targeted biopsies should be performed
B. Only systematic biopsies should be performed
C. Both targeted and systematic biopsies should be performed
D. No biopsy is necessary
C. Both targeted and systematic biopsies should be performed
Explanation: The AUA position recommends that both targeted and systematic biopsies be performed in men undergoing MRI-targeted sampling.
According to the PIRADS v2.1 scoring system, what PIRADS score indicates that clinically significant cancer is highly likely to be present?
A. 1
B. 2
C. 3
D. 5
D. 5
Explanation: According to the PIRADS v2.1 scoring system, a PIRADS score of 5 indicates that clinically significant cancer is highly likely to be present.
What is the purpose of using the PIRADS v2.1 system in mpMRI?
A. To identify and score lesions for the level of suspicion for harboring clinically significant prostate cancer
B. To measure the size of the prostate gland
C. To detect benign conditions of the prostate
D. To determine the age of the patient
A. To identify and score lesions for the level of suspicion for harboring clinically significant prostate cancer
Explanation: The PIRADS v2.1 system is used in mpMRI to identify and score lesions, delineating the level of suspicion for harboring clinically significant prostate cancer.
According to the PRECISION study, what is the potential benefit of using mpMRI with targeted biopsy over standard TRUS prostate biopsy?
A. Detects more clinically significant prostate cancer
B. Fewer men receive a diagnosis of clinically insignificant cancer
C. Both A and B
D. None of the above
C. Both A and B
Explanation: The PRECISION study found that clinically significant prostate cancer was detected more often in the mpMRI targeted biopsy group compared to the TRUS biopsy group, and fewer men in the mpMRI targeted biopsy group received a diagnosis of clinically insignificant cancer.
What is the associated risk of prostate cancer detection with a positive mpMRI result for men with a prior negative biopsy with continued PSA rise?
A. 10-30%
B. 34-68%
C. 70-85%
D. 90-100%
B. 34-68%
Explanation: The associated risk of prostate cancer detection with a positive mpMRI result in men with a prior negative biopsy with continued PSA rise is 34-68%.
What does a PIRADS score of 3 indicate in the PIRADS v2.1 scoring system?
A. Very low risk of clinically significant cancer
B. Low risk of clinically significant cancer
C. Intermediate risk or the presence of clinically significant cancer is equivocal
D. High risk of clinically significant cancer
C. Intermediate risk or the presence of clinically significant cancer is equivocal
Explanation: According to the PIRADS v2.1 scoring system, a score of 3 indicates that the presence of clinically significant cancer is equivocal.
In the TRIO study, how much did the combined biopsy approach increase overall prostate cancer detection compared to either biopsy method alone?
A. 2.5%
B. 5.5%
C. 9.9%
D. 15.4%
C. 9.9%
Explanation: In the TRIO study, the combined biopsy approach led to a 9.9% increase in overall prostate cancer detection compared to either biopsy method alone.
Which urine-based test measures DLX1 and HOXC6 against KLK3 mRNA levels in post-DRE urine and is validated for the risk of clinically significant prostate cancer (≥3+4) in men without a prior biopsy?
A. ExoDx™
B. miR
C. MPS (MyProstateScore, formerly Michigan Prostate Score (MiPS))
D. SelectMDx
D. SelectMDx
Explanation: SelectMDx is a urine-based test that measures DLX1 and HOXC6 against KLK3 mRNA levels in post-DRE urine and is validated for the risk of clinically significant prostate cancer.
Which of the following blood-based tests uses PSA, percent free PSA, and [-2]proPSA to estimate the risk of clinically significant prostate cancer?
A. 4-kallikrein (4Kscore®) panel
B. PHI
C. Both A and B
D. None of the above
B. PHI
Explanation: PHI is a blood-based test that uses PSA, percent free PSA, and [-2]proPSA to estimate the risk of clinically significant prostate cancer.
Which tissue-based test is assessed on non-cancerous biopsy tissue and is validated to predict the absence of prostate cancer on subsequent biopsy?
A. OncotypeDX Prostate
B. Prolaris
C. ProMark
D. ConfirmMDx
D. ConfirmMDx
Explanation: ConfirmMDx is a tissue-based test that is assessed on non-cancerous biopsy tissue and is validated to predict the absence of prostate cancer on subsequent biopsy.
What does the Decipher test predict?
A. Risk of urinary tract infection
B. Risk of benign prostatic hyperplasia
C. Risk of metastasis, used to select patients who are better treated with definitive therapy
D. Risk of prostatitis
C. Risk of metastasis, used to select patients who are better treated with definitive therapy
Explanation: The Decipher test is a 22-gene genomic classifier that is validated to predict the risk of metastasis, and it’s used to select patients who are better treated with definitive therapy.
What is the role of the ExoDx test in prostate cancer screening?
A. It measures the levels of PSA in the blood.
B. It is a urine-based 3-gene exosome expression assay validated for the risk of clinically significant prostate cancer in men without a prior biopsy.
C. It is a tissue-based test that predicts the risk of prostate cancer on subsequent biopsy.
D. It is a blood-based test that predicts the risk of clinically significant prostate cancer.
B. It is a urine-based 3-gene exosome expression assay validated for the risk of clinically significant prostate cancer in men without a prior biopsy.
Explanation: According to the text, the ExoDx test is a urine-based 3-gene exosome expression assay validated for the risk of clinically significant prostate cancer in men without a prior biopsy.
Which test uses a 17-gene expression panel to predict the risk of adverse pathology at surgery and the risk of metastasis and death after treatment?
A. OncotypeDX Prostate
B. Prolaris
C. ProMark
D. Decipher
A. OncotypeDX Prostate
Explanation: The OncotypeDX Prostate test uses a 17-gene expression panel to predict the risk of adverse pathology at surgery and the risk of metastasis and death after treatment.
What is the function of the 4-kallikrein (4Kscore®) panel in the screening and diagnosis of prostate cancer?
A. It’s a blood-based validated risk assessment for clinically significant prostate cancer in men at risk.
B. It’s a urine-based test that measures DLX1 and HOXC6 against KLK3 mRNA levels.
C. It’s an epigenetic test of the prostate cancer-associated genes GSTP1, APC, and RASSF1.
D. It’s a tissue-based test that predicts the risk of prostate cancer on subsequent biopsy.
What is the function of the 4-kallikrein (4Kscore®) panel in the screening and diagnosis of prostate cancer?
A. It’s a blood-based validated risk assessment for clinically significant prostate cancer in men at risk.
B. It’s a urine-based test that measures DLX1 and HOXC6 against KLK3 mRNA levels.
C. It’s an epigenetic test of the prostate cancer-associated genes GSTP1, APC, and RASSF1.
D. It’s a tissue-based test that predicts the risk of prostate cancer on subsequent biopsy.
Which test, according to the table, has the highest area under curve (AUC) value?
A. ExoDx
B. miR
C. 4K Score
D. Decipher
B. miR
Explanation: According to the table, the miR test has an AUC of 0.98 – 0.99, which is higher than the other tests listed in the options.
What does the SelectMDx test measure and in what type of sample?
A. DLX1 and HOXC6 against KLK3 mRNA levels in post-DRE urine
B. Serum PSA, post-DRE urine PCA3 and TMPRSS2:ERG
C. PSA, percent free PSA, and [-2]proPSA in blood
D. GSTP1, APC, and RASSF1 in non-cancerous biopsy tissue
A. DLX1 and HOXC6 against KLK3 mRNA levels in post-DRE urine
Explanation: According to the text, the SelectMDx test measures DLX1 and HOXC6 against KLK3 mRNA levels in post-DRE urine.
Table 2
Table 3
What is the minimum recommended number of core samples in a systematic prostate biopsy (PBx) to establish a Prostate Cancer (PCa) diagnosis?
A. 6
B. 12
C. 18
D. 24
B. 12
Explanation: A minimum of 12-core systematic PBx is recommended to establish PCa diagnosis.
In the case of locally advanced or metastatic prostate cancer, what type of biopsy can be used?
A. Six-core “sextant” biopsy
B. Eight-core biopsy
C. Ten-core biopsy
D. Twelve-core biopsy
A. Six-core “sextant” biopsy
Explanation: For obvious locally advanced or metastatic disease a six-core “sextant” biopsy can be employed.
What should the positive biopsy rates be for biopsy naïve patients with elevated PSA using standard systematic TRUS biopsy?
A. 20-25%
B. 30-35%
C. 40-45%
D. 50-55%
C. 40-45%
Explanation: Positive biopsy rates with standard systematic TRUS biopsy should be ~40-45% for biopsy naïve patients with elevated PSA.
Why should biopsy cores be labeled by location during the process?
A. It helps in preventing tangling of cores.
B. It improves tissue sampling.
C. It determines the location of disease and aids in treatment planning.
D. All of the above.
C. It determines the location of disease and aids in treatment planning.
Explanation: Cores should be labeled by location as this information can determine location of disease and treatment planning.